8-K 1 v68491e8-k.txt FORM 8-K 1 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ------------------------- FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Janaury 11 2001 ------------------------------------ (Date of Report) NEORX CORPORATION -------------------------------------------------------------------------------- (EXACT NAME OF REGISTRANT AS SPECIFIED IN CHARTER) WASHINGTON 0-16614 91-1261311 ----------------------------- ---------------------- ----------------------- (State or Other Jurisdiction (Commission File No.) (IRS Employer of Incorporation) Identification No.) 410 WEST HARRISON STREET, SEATTLE, WASHINGTON 98119-4007 -------------------------------------------------------------------------------- (Address of principal executive offices) (Zip Code) (206) 281-7001 -------------------------------------------------------------------------------- (Registrant's telephone number, including area code) 2 ITEM 5. OTHER EVENTS NeoRx Corporation suspends accrual on its STR trials pending resolution with FDA See Exhibit 99.1 for additional information. ITEM 7. EXHIBITS 99.1 Press release dated January 10, 2001 3 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEORX CORPORATION Dated: January 11, 2001 By /s/ RICHARD L. ANDERSON ----------------------- Richard L. Anderson President and Chief Operating Officer -2- 4 EXHIBIT INDEX Exhibit No. 99.1 Press Release dated January 10, 2001